English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Giuseppe Curigliano, MD, PhD, is Senior Deputy Director at the European Institute of Oncology, Division of Medical Oncology, in Milan, Italy. He is a clinician and researcher specializing in breast cancer. Dr. Curigliano earned his MD at the Universita Cattolica del Sacro Cuore, in Rome, Italy, and also holds a PhD in clinical pharmacology from the University of Pisa. His academic awards include the Toniolo Institute Prize for Medical Research and the AIRC Triennal National Research Grant. He is an active member of ASCO and the European Society of Medical Oncology and a founding member of and scientific coordinator for the International Cardio-Oncology Society. He is member of the Scientific Committee of the International Breast Cancer Study Group. Dr. Curigliano’s research experiences include principle or coinvestigator work in primary chemotherapy and primary chemo-endocrine therapy in breast cancer, with a strong background in preclinical and phase I studies. He is also the coordinator of a research platform on new drug development in breast cancer. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, and European Journal of Cancer. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, and the Journal of the National Cancer Insititute.

Personalizing Medicine Through Personalized Communication: Individuality of the Patient Across Borders and Cultures